Sanofi(US:SNY) 智通财经网·2026-02-13 07:55Core Viewpoint - Sanofi is undergoing a leadership change with Belén Garijo set to become the first female CEO, facing the challenge of revitalizing the company's stagnant drug development and addressing vaccine skepticism during Donald Trump's presidency [1][2]. Group 1: Leadership Transition - Paul Hudson, the former CEO, is leaving the company, and Garijo will take over in April [1]. - Garijo has a strong track record at Merck Group, where she managed a diverse business portfolio and successfully negotiated key pricing agreements [1][2]. - The board's patience has worn thin due to the lack of results from increased R&D investments, with Sanofi's stock down 25% over the past year [1]. Group 2: R&D Challenges - Developing new drugs remains a significant issue for Sanofi, particularly the need to find a replacement for Dupixent, which accounts for over 30% of the company's revenue [2]. - The vaccine segment, contributing nearly 20% to revenue, has also seen declining sales, attributed to a less favorable attitude from the U.S. health department [2]. Group 3: Garijo's Background and Expectations - Garijo is recognized for her operational execution and attention to detail, but her tenure at Merck saw only three new drugs successfully launched [8]. - Investors and analysts express mixed feelings about her ability to revitalize Sanofi's R&D, noting her operational experience may not fully translate to scientific innovation [9]. - There are speculations about her being a transitional CEO, with expectations for her to drive change but uncertainty about her long-term position [9].